IP Library Granted Patent US 10,513,518
Granted Patent B2
US 10,513,518 · App. 15/544,295 · Granted Dec 24, 2019

Inhibitors of the renal outer medullary potassium channel

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,513,518
App. No.
15/544,295
Granted
Dec 24, 2019
Kind
B2
Abstract

The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Claims (28)

1. A compound having structural Formula Ia, Formula Ib, Formula Id, Formula Ie, Formula If, or Formula Ig:

or a pharmaceutically acceptable salt thereof, wherein:

R 2 is H, or C 1-4 alkyl;

R 3 is H, or —C 1-3 alkyl optionally substituted with —OH, —OCH 3 or 1 to 3 halo, or R 3 and R 4 are joined together to form —CH 2 —CH 2 —;

R 4 is —H, or —C 1-3 alkyl optionally substituted with —OH, —OCH 3 or 1 to 3 halo, or R 3 and R 4 are joined together to form —CH 2 —CH 2 —;

R 5 is —H, halo, —C 3-6 cycloalkyl or —C 1-3 alkyl;

Z is

Y 1 , Y 2 , Y 3 and Y 4 are each independently selected from C(R 9 ) or N;

provided that at most two of Y 1 , Y 2 , Y 3 and Y 4 are N;

each R 9 is independently —H, halo, OC 1-4 alkyl or C 1-4 alkyl optionally substituted with 1-3 of halo;

R 10 is —H, halo, or C 1-4 alkyl optionally substituted with 1-3 halo;

R 11 is —H, C 1-4 alkyl optionally substituted with 1-3 halo; and

R 12 is —H or C 1-4 alkyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein each of R 3 and R 4 are —H, or R 3 and R 4 are joined together to form —CH 2 CH 2 —.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is —H or —CH 3 .

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is —H.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5 is —CH 3 .

6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is

wherein each of the variables Y 1 , Y 2 , Y 3 and Y 4 , are as defined in claim 1 .

7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is

wherein each of the variables R 10 , R 11 , and R 12 are as defined in claim 1 .

8. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z, if present, is

9. A compound which is:

or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 10 , further comprising an additional active agent selected from losartan, valsartan, candesartan, olmesartan, telmesartan, eprosartan, irbesartan, amlodipine, alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltipril, perindopril, quinapril, ramipril, spirapril, temocapril, trandolapril, amiloride, spironolactone, epleranone or triamterene, or a pro-drug thereof, or a pharmaceutically acceptable salt of any of the foregoing.

12. A method for causing diueresis, natriuresis or both, comprising administering a compound of claim 1 or a pharmaceutically acceptable salt thereof in a therapeutically effective amount to a patient in need thereof.

13. A method for the treatment of one or more disorders selected from hypertension, acute heart failure, chronic heart failure, pulmonary arterial hypertension, cardiovascular disease, diabetes, endothelial dysfunction, diastolic dysfunction, stable and unstable angina pectoris, thromboses, restenosis, myocardial infarction, stroke, cardiac insufficiency, pulmonary hypertonia, atherosclerosis, hepatic cirrhosis, ascitis, pre-eclampsia, cerebral edema, nephropathy, nephrotic syndrome, acute kidney insufficiency, chronic kidney disease, hypercalcemia, Dent's disease, Meniere's disease, or edematous states comprising administering a compound of claim 1 or a pharmaceutically acceptable salt thereof in a therapeutically effective amount to a patient in need thereof.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2017
From: DEJESUS, REYNALDA K.; FU, QINGHONG; JIANG, JINLONG; TANG, HAIFENG
To: MERCK SHARP & DOHME CORP.
Reel/Frame 043087/0307 →